Hospira suffers setback as two patents invalidated
21-12-2018
Hospira appeals against $70m Amgen verdict
02-10-2017
Federal Circuit rejects Amgen biosimilar discovery request
11-08-2017
oonal / iStockphoto.com
Amgen has secured $70 million in damages from a jury in a biosimilar dispute with Hospira.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Amgen, Hospira, patent, patent infringement, biosimilar, Biologics Price Competition and Innovation Act, anaemia
